Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Shortage of generic...

    Shortage of generic version of BP drug pindolol, says Sun Pharma

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-03T12:36:07+05:30  |  Updated On 3 March 2020 12:36 PM IST
    Shortage of generic version of BP drug pindolol, says Sun Pharma

    The coronavirus outbreak has disrupted international businesses dependent on Chinese supplies and industry experts expect Indian generic drugmakers to face supply shortages from China if epidemic drags on.

    Bengaluru: Indian drugmaker Sun Pharmaceutical Industries Ltd reported a shortage of its generic version of hypertension drug pindolol, due to a lack of pharmaceutical ingredients while stressing the shortfall does not stem from China.

    Indian companies are the main supplier of generic drugs to the world and procure almost 70% of the active pharmaceutical ingredients (APIs) for their medicines from China.

    The coronavirus outbreak has disrupted international businesses dependent on Chinese supplies and industry experts expect Indian generic drugmakers to face supply shortages from China if epidemic drags on.

    "At the moment, we haven't seen any major disruption in API supplies due to the coronavirus outbreak in China," Sun Pharma reiterated, without giving details on the reasons for the shortfall in pindolol ingredients.

    "We have sufficient inventory of API and raw materials for the short term," it added.

    The company did not immediately respond to Reuters requests for further details on the reasons for the shortage of the API for the drug.

    Last week, the U.S. Food and Drug Administration announced the first coronavirus-related drug shortage in the United States but declined to name the drug in question, leaving industry players debating which medicines were at risk.

    Sun Pharma reiterated that there had been some impact on supplies for a few APIs, but again gave no details on which drugs might be affected.

    The FDA's website, which lists shortfalls in supplies of medicines as they occur, now shows a shortage of the pindolol tablets.

    Pindolol, sold under the brand name Visken by Novartis, is an orally administered drug used alone or with other medications to treat high blood pressure.

    Other generic drugmakers in India say they currently have enough API supplies from China to cover their operations for up to about three months.

    Read also: Sun Pharma arm- SPARC application for cancer drug Taclantis rejected by USFDA

    sun-pharmahypertensiondrug-shortagepindololcoronaviruscovid-19generic medicine

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok